Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 3
Submit an article Journal homepage
61
Views
10
CrossRef citations to date
0
Altmetric
Miscellaneous

Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?

Sheila A Doggrell Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. [email protected]
Pages 339-342 | Published online: 22 Apr 2005

Bibliography

  • RINALDI-CARMONA M, BARTH F, CONGY C et al: SR-147778 [544-bromopheny0-1- (2,4-dichloropheny1)-4-ethyl-N- (1-piperidiny1)-1H-pyrazole-3-carboxamidel, a potent and selective antagonist of the CB, cannabinoid receptor: biochemical and pharmacological characterisation. Pharmacol Exp. Ther. (2004) 310:905–910.
  • GESSA GL, SERRA S, VACCA G, CARAT MAM, COLOMBO G: Suppressing effect of the cannabinoid CBI receptor antagonist, SR-147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol Alcohol. (2005) 40:46–53.
  • PETERS A, BARENDREGT JJ, WILLEKENS F et al: Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann. Intern. Med. (2003) 138:24–32.
  • MANN K: Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs (2004) 18:485–504.
  • WHITWORTH AB, FISCHER F, LESCH OM et al: Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet (1996) 347:1438–1442.
  • RINALDI-CARMONA M, BARTH F, HEAULME M et al.: SR-147778, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. (1994) 350:240–244.
  • ARNONE M, MARUANI J, CHAPERON F et al.: Selective inhibition of sucrose and ethanol intake by SR-141716, an antagonist of central cannabinoid (CBI) receptors. Psychopharmacology (1997) 132:104–106.
  • SERRA S, BRUNETTI G, PANT M et al:Blockade by the cannabinoid CBI receptor antagonist, SR 141716, of alcohol deprivation effect in alcohol-preferring rats. Eur. Pharmacol (2002) 443:95–97.

Website

  • http://www. drugdeve lopment-technology. corn/ proj ect_printable.asp?ProjectID=2674

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.